General Information of Drug (ID: DMHVEGJ)

Drug Name
CC-930
Synonyms
TANZISERTIB; CC-930; 899805-25-5; CC 930; UNII-M5O06306UO; CHEMBL1950289; M5O06306UO; CC930; Trans-4-({9-[(3s)-Tetrahydrofuran-3-Yl]-8-[(2,4,6-Trifluorophenyl)amino]-9h-Purin-2-Yl}amino)cyclohexanol; Tanzisertib [USAN:INN]; 3tti; trans-4-((9-((3S)-Tetrahydrofuran-3-yl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)cyclohexanol; Tanzisertib (USAN); CC-930(Tanzisertib); SCHEMBL2133061; SCHEMBL4760419; SCHEMBL2133055; GTPL9836; SCHEMBL8082102; SCHEMBL15589918; CHEMBL1950305; SCHEMBL10179476; JNK-930; MolPort-044-562-358
Indication
Disease Entry ICD 11 Status REF
Discoid lupus erythematosus EB51.0 Phase 2 [1]
Idiopathic pulmonary fibrosis CB03.4 Phase 2 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 448.4
Logarithm of the Partition Coefficient (xlogp) 3.1
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 10
Chemical Identifiers
Formula
C21H23F3N6O2
IUPAC Name
4-[[9-[(3S)-oxolan-3-yl]-8-(2,4,6-trifluoroanilino)purin-2-yl]amino]cyclohexan-1-ol
Canonical SMILES
C1COC[C@H]1N2C3=NC(=NC=C3N=C2NC4=C(C=C(C=C4F)F)F)NC5CCC(CC5)O
InChI
InChI=1S/C21H23F3N6O2/c22-11-7-15(23)18(16(24)8-11)28-21-27-17-9-25-20(26-12-1-3-14(31)4-2-12)29-19(17)30(21)13-5-6-32-10-13/h7-9,12-14,31H,1-6,10H2,(H,27,28)(H,25,26,29)/t12?,13-,14?/m0/s1
InChIKey
IBGLGMOPHJQDJB-MOKVOYLWSA-N
Cross-matching ID
PubChem CID
11597537
CAS Number
899805-25-5
DrugBank ID
DB11798
TTD ID
D0X4MN
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Jun N terminal kinase (JNK) TTR2TXZ MK08_HUMAN ; MK09_HUMAN ; MK10_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01203943) A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF). U.S. National Institutes of Health.
2 In vitro metabolism of a novel JNK inhibitor tanzisertib: interspecies differences in oxido-reduction and characterization of enzymes involved in metabolism. Xenobiotica. 2015;45(6):465-80.